TEVA

Johnson & Johnson’s JNJ second-quarter 2026 earnings came in at $2.90 per share, which beat the Zacks Consensus Estimate of $2.84. Earnings rose 4.7% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.27 per share, down 0.9% year over year. Sales of this drug and medical devices giant came in at $25.3 billion, which marginally beat the Zacks Consensus Estimate of $25.2 billion. Sales rose 6.6% from the year-ago quarter, reflecting an operational increase of 5.6% and a positive currency impact of 1.0%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 5.7% on an operational basis. Second-quarter sales in the domestic market rose 7.3% to $14.53 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 7.4% in the quarter. International sales rose 5.7% on a reported basis to $10.8 billion, reflecting an operational increase of 3.4% and a positive currency impact of 2.3%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 3.5% in the quarter. Innovative Medicine sales rose 7.8% year over year to $16.38 billion. Operational sales increased 6.8%, while adjusted operational growth was 6.9%. U.S. sales advanced 8.9%, and international sales increased 6% on a reported basis. Innovative Medicines sales slightly beat the Zacks Consensus Estimate of $16.16 billion. Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment’s growth. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. These gains were partly offset by lower sales of Stelara, Remicade, Imbruvica and Zytiga. Worldwide oncology sales increased 17.3% to $7.41 billion. Sales of blockbuster multiple myeloma medicine Darzalex rose 18.9% to $4.21 billion in the quarter. Sales beat the Zacks Consensus Estimate of $4.16 billion. Imbruvica sales declined 18.6% to $599 million. Rising competitive pressure in the United States due to new oral competition has been hurting Imbruvica's sales for the past few quarters. Imbruvica sales missed the Zacks Consensus Estimate of $630.0 million. Erleada sales increased 9.5% to $995 million. Erlea...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Teva Pharmaceutical Industries (NYSE:TEVA) reported encouraging 24 week Phase 1b data for its anti IL 15 antibody in vitiligo. The investigational monoclonal antibody showed clinically meaningful improvements in patients with limited existing treatment options. Teva plans to advance the asset into a Phase 2b trial in vitiligo later this year, with additional work targeting immune mediated conditions such as celiac disease. Teva Pharmaceutical Industries enters this update with the stock at $32.95 and a 3 year return of 310.8%. Over the past year, NYSE:TEVA is up 100.7%, while year to date the shares are up 6.5%, despite declines of 6.6% over the past week and 4.9% over the past month. The anti IL 15 antibody sits within a broader biopharma push that investors increasingly track alongside Teva's established generics business. For investors tracking NYSE:TEVA, the progress of this antibody through Phase 2b and into potential additional indications such as celiac disease could become a reference point in assessing Teva's evolving R&D profile. The current news does not change any fundamentals on its own, but it adds a datapoint for readers considering how much weight to place on Teva's biopharma pipeline relative to its current $32.95 share price and recent return profile. Stay updated on the most important news stories for Teva Pharmaceutical Industries by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Teva Pharmaceutical Industries. We've flagged 2 risks for Teva Pharmaceutical Industries. See which could impact your investment. ✅ Price vs Analyst Target: Teva Pharmaceutical Industries trades at US$32.95 versus a US$40.90 analyst target, about 19% below consensus. ✅ Simply Wall St Valuation: The stock is described as trading 48.7% below an estimated fair value. ❌ Recent Momentum: The share price is down 4.9% over the past 30 days. There's only one way to know the right time to buy, sell or hold Teva Pharmaceutical Industries. Head to Simply Wall St's company report for the latest analysis of Teva Pharmaceutical Industries's Fair Value. 📊 The anti IL 15 Phase 1b data and move into Phase 2b gives Teva Pharmaceutical Industries an...

Johnson & Johnson JNJ will begin the earnings season for the drug & biotech sector when it reports its second-quarter 2026 results on July 15. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $25.18 billion and $2.85 per share, respectively. The Zacks Consensus Estimate for 2026 earnings has risen from $11.57 per share to $11.58 over the past 60 days, while that for 2027 earnings has gone up from $12.58 per share to $12.63 over the same time frame. Image Source: Zacks Investment Research The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 1.89%, on average. In the last reported quarter, the company delivered an earnings surprise of 1.12%. Image Source: Zacks Investment Research J&J has an Earnings ESP of +2.08% and a Zacks Rank #3 (Hold), indicating a likely positive surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here. Sales in J&J’s Innovative Medicine segment are expected to have been driven by higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains. The Zacks Consensus Estimate for Darzalex, Tremfya and Erleada is pegged at $4.16 billion, $1.85 billion and $1.05 billion, respectively. Other products like Uptravi and Opsumit are likely to have witnessed continued growth. The rapid adoption of new drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato is likely to have contributed to top-line growth. However, sales of Xarelto, Simponi/Simponi Aria and Remicade declined in the first quarter, a trend likely to have continued in the second quarter. J&J’s newly launched therapy, Inlexzo, for certain types of bladder cancer, generated sales of slightly above $30 million in the first quarter. J&J received a permanent J-code for Inlexzo reimbursement in April that should have boosted patient access and sales for the therapy in the second quarter. Investors will also look out for initial sales numbers of its newly launched...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Teva Pharmaceutical Industries stock has delivered a very strong 310.8% return over the past three years, yet the current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a large discount while market multiples look closer to fair. A roughly 3x gain over three years can reset expectations, so recent buyers may be taking on a very different risk profile than those who entered earlier in the move. Progress in higher value biopharmaceuticals, including programs like TEV-408 and new biosimilar partnerships, can support cash flow expectations. At the same time, execution risk around the pipeline and regulatory outcomes may weigh on how reliable those future cash flows appear. Teva screens as undervalued on 4 of 6 checks, a mixed picture rather than a clear bargain or clear overvaluation, according to its value score of 4/6. The issue now is whether Teva Pharmaceutical Industries' recent share price sits far enough below the DCF based intrinsic value estimate to compensate investors for the risks embedded in its turnaround and pipeline. Teva Pharmaceutical Industries delivered 100.7% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. The Discounted Cash Flow (DCF) model values Teva Pharmaceutical Industries by projecting the cash it may generate for shareholders and discounting that back to today. In this approach, Teva’s latest twelve month free cash flow of about $1.2b is treated as recovering and growing over time, which leads to an estimated intrinsic value of around $64 per share. Compared with the current share price, that calculation implies roughly a 48.7% discount, so the stock screens as undervalued on this model. The DCF assumes that pipeline and biosimilar efforts translate into higher future free cash flow, and that those dollars remain available to equity holders after debt servicing. Because the recent move to advance TEV-408 into a Phase 2b trial adds another potential high value asset to Teva Pharmaceutical Industries, the market’s lower pricing relative to this cash flow based estimate suggests investors are still applying a meaningful risk discount. Overall, the Discounted Cash Flo...

GOLETA, Calif., July 13, 2026--(BUSINESS WIRE)--Deckers Brands (NYSE:DECK), a global leader in designing, marketing and distributing innovative footwear, apparel and accessories, today announced that the Company's conference call to review first quarter fiscal 2027 results will be on Thursday, July 23, 2026 at approximately 4:30 pm Eastern Time. The broadcast will be hosted at ir.deckers.com. The broadcast will be available for at least 30 days following the conference call. About Deckers Brands Deckers Brands is a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories developed for both everyday casual lifestyle use and high-performance activities. The Company’s portfolio of brands includes UGG®, HOKA®, and Teva®. Deckers Brands products are sold in more than 50 countries and territories through select department and specialty stores, Company-owned and operated retail stores, and select online stores, including Company-owned websites. Deckers Brands has over 50 years of history building niche footwear brands into lifestyle market leaders attracting millions of loyal consumers globally. For more information, please visit www.deckers.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260713208995/en/ Contacts Investor Relations Contact: Erinn Kohler | VP, Investor Relations, Corporate Planning & Business Analytics | 805.967.7611

Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date Nearly 75% of patients reported improvement in facial vitiligo, with half reporting “much’ or “very much” improved TEV-’408 is designed for convenient quarterly (Q12W) subcutaneous dosing Teva will hold an investor call and live webcast today,Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data. TEL AVIV, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV). Data from the ongoing, open-label Phase 1b study showed improvements in skin pigmentation in patients with active or stable NSV. TEV-’408 was well-tolerated with no safety signals observed to date. At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area, representing a population with limited treatment options. At week 24, in evaluable participants: Nearly 75% of patients reported improvement in facial vitiligo, with half reporting “much” or “very much” improved 42% achieved F-VASI50 and 21% achieved F-VASI75 55% of patients reported improvement in total body vitiligo 7% achieved T-VASI50 “TEV-’408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline,” said Richard Francis, President and Chief Executive Officer of Teva. “Grounded in compelling biology and focused on meaningful unmet need, TEV-’408 reflects our progress in our Pivot to Growth strategy and our commitment to pursuing differentiated innovation for patients.” Vitiligo is a chronic autoimmune disease that causes loss of skin pigmentation and can have a significant impact on quality of life, self-image, and daily social interactions. Despite recent advances, treatment options remain limited, particularly for patients with more extensive disease, who may require systemic therapy, or those seeking better disease control. “Vitiligo can affect far more than the skin. I...

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best weight loss drugs on this list. TheFly reported on June 8 that TEVA announced new clinical and real-world findings supporting the use of Austedo and Austedo XR in patients with tardive dyskinesia. Results from the IMPACT-TD study showed that patients with mild symptoms experienced improvements in involuntary movements and daily functioning after treatment. The company also reported updated data from the ongoing three-year RIM-TD study, where more than half of participants achieved a treatment response by week 15, while additional patients showed benefits with continued therapy beyond that period. The findings highlighted the potential value of long-term treatment and reinforced Teva’s efforts to improve disease management and outcomes for individuals living with tardive dyskinesia. Second, it was announced on June 4 that Teva Pharmaceutical Industries Limited (NYSE:TEVA) expanded its footprint in international markets through the European rollout of AHZANTIVE, an aflibercept biosimilar. The launch began across several countries, including France, Germany, Spain, and the Netherlands, with additional market entries planned later in the year. The product broadens TEVA’s biosimilars portfolio and strengthens its position in ophthalmology. Approved for multiple retinal disorders, AHZANTIVE offers an additional treatment option for patients with vision-threatening conditions. The launch also reflects TEVA’s strategy of increasing access to biologic medicines through partnerships, commercial expansion, and a growing biosimilars business. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a global pharmaceutical company advancing its growth strategy through generic GLP-1 treatments. By launching generic versions of liraglutide-based weight-loss and diabetes drugs, Teva aims to improve affordability and access in the growing obesity treatment market. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks...

TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. Cautionary Note Regarding Forward-Looking Statements This Document and the presentation at the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our ability to successfully execute our Pivot to Growth strategy, including to exp...

This article first appeared on GuruFocus. Release Date: June 16, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Medincell SA (STU:MEB) has successfully executed its Shift to Growth strategy, with strong performance across its three growth engines: Risperidone LAI, Holonza PIN LAI, and ABBI Number One. The company reported a significant increase in royalties from UZD, with net sales by Teva reaching $215 million, up from $141 million the previous year. Olanzapine LAI is on track for a U.S. launch in the fourth quarter of 2026, with regulatory paths clearly defined and submissions accepted by the FDA. Medincell SA (STU:MEB) is expanding its pipeline with 15 active programs at the formulation stage, focusing on high-value indications. The company maintains a strong financial position with EUR 85 million in cash, providing long-term financial visibility and flexibility to support growth strategies. Total income for the fiscal year was $24.3 million, slightly lower than the previous year's $27.7 million, primarily due to the absence of milestone payments. Operating expenses increased to EUR 45 million from EUR 38.5 million, reflecting strategic investments but also impacting short-term profitability. The company reported an operating loss of EUR 20.8 million, attributed to the absence of milestone payments and variability in R&D revenues. Exposure to foreign exchange fluctuations, particularly between USD and EUR, poses a challenge, with royalties labeled in USD while many expenses are in EUR. The anticipated regulatory path changes for the six-month contraceptive program could delay its initiation, impacting the timeline for this potential growth area. Warning! GuruFocus has detected 3 Warning Signs with STU:MEB. Is STU:MEB fairly valued? Test your thesis with our free DCF calculator. Q: Can you comment on Teva's conservative guidance for USEDI and expectations for Olanzapine LAI's market availability? A: (Christophe Duarte, CEO) Teva's policy is to be conservative with guidance. For USEDI, initial guidance was often exceeded. We expect Olanzapine LAI to launch immediately upon approval. Q: What do the business development expenses consist of, and how do you manage foreign exchange exposure? A: (Stefan Postic, CFO) Business development expenses cover personnel costs for global expansion. We manage foreig...

A year marked by solid execution, with Continued UZEDY® ramp-up, supporting royalty growth Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva1 The first AbbVie program progressing toward the initiation of clinical development The expansion of both partnered and internal R&D pipelines Continued strengthening of the technology platform MONTPELLIER, France, June 16, 2026--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Medincell continues to transition towards multiple commercialized innovative products based on its technology, increasingly supporting milestone and recurring royalty revenues. FY 2025–26 reflects this trend, with strong growth in UZEDY® royalties and a disciplined increase in investments to support future growth. As anticipated, year-over-year comparisons are impacted by the absence of non-recurring milestone revenues recorded in the prior year, which affects the comparability of total revenues. Christophe Douat, CEO of Medincell, said: "FY 2025–26 reflects an important transition phase for Medincell. Building on UZEDY’s strong performance and the expected commercial launch of Olanzapine LAI by our partner Teva later this year, we are advancing the next phase of our ‘Shift to Growth’ strategy. We are building a pipeline of highly differentiated, innovation-driven products designed to deliver sustainable value for patients, partners and shareholders, while generating milestones and recurring high-margin revenues over time." For the full press release, please click on the following link: https://www.medincell.com/news/ About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact. medincell.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260616763165/en/ Contacts David Heuzé Head of Corporate and Financial Communications, and [email protected] / +33 (0)6 83 25 21 86Grace Kim Chief Strategy Officer, U.S. [email protected] / +1 (646) 991-4023

GOLETA, Calif., May 11, 2026--(BUSINESS WIRE)--Deckers Brands (NYSE:DECK), a global leader in designing, marketing and distributing innovative footwear, apparel and accessories, today announced that the Company's conference call to review fourth quarter and full fiscal year 2026 results will be on Thursday, May 21, 2026 at approximately 4:30 pm Eastern Time. The broadcast will be hosted at ir.deckers.com. The broadcast will be available for at least 30 days following the conference call. About Deckers Brands Deckers Brands is a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories developed for both everyday casual lifestyle use and high-performance activities. The Company’s portfolio of brands includes UGG®, HOKA®, and Teva®. Deckers Brands products are sold in more than 50 countries and territories through select department and specialty stores, Company-owned and operated retail stores, and select online stores, including Company-owned websites. Deckers Brands has over 50 years of history building niche footwear brands into lifestyle market leaders attracting millions of loyal consumers globally. For more information, please visit www.deckers.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511808163/en/ Contacts Investor Relations Contact: Erinn Kohler | VP, Investor Relations, Corporate Planning & Business Analytics | 805.967.7611

Interested in Alvotech? Here are five stocks we like better. FDA inspection at Alvotech’s Reykjavik facility is underway and Biologics License Application resubmissions for multiple biosimilars are in the final stage, with the company planning resubmissions in Q2 and targeting Q4 approvals. Facility quality improvements have reduced manufacturing throughput, and Alvotech signed a deal with Fujifilm to add U.S. capacity; technology transfer is underway with product supply to the U.S. expected in the second half of 2027. Commercially, AVT02 (Humira biosimilar) is the fastest-growing U.S. Humira biosimilar at about 10% of the biosimilar segment, while Q1 revenue fell 20% to $106 million; management reaffirmed full-year revenue guidance of $650–$700M and adjusted EBITDA guidance of $180–$220M. Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem Alvotech (NASDAQ:ALVO) executives said the company’s first-quarter priorities centered on advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercial activity globally as the biosimilar developer works through manufacturing enhancements at its Reykjavik facility. Founder and Executive Chairman Róbert Wessman said the company spent the quarter “progressing the FDA resubmission, maintaining a high level of inspection readiness, and continuing to expand our commercial business globally.” He noted the U.S. Food and Drug Administration began a “routine GMP surveillance inspection” at Alvotech’s Reykjavik facility last week, with the inspection “currently ongoing.” Wessman said the company expects it to conclude “by the end of business day tomorrow,” adding that routine surveillance inspections are a normal part of operating an FDA-regulated manufacturing site. → Berkshire Hathaway’s Record Cash Hoard: Why and What's Next? 2 Generic Drug Makers With Growing Runways Wessman also referenced steps taken since the company’s most recent pre-license inspection in July 2025. He said Alvotech has implemented “important enhancements across our quality system and the operations,” and that work to address findings is “well advanced.” He added the company “deliberately taken additional time to substantially de-risk future operational and regulatory disruption” and to ensure its resubmissions “fully address the Agency’s requirements.” According to Wessman, the resubmission of Biologics License Ap...